Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Current Assets (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Current Assets for 4 consecutive years, with $485.1 million as the latest value for Q4 2025.

  • For Q4 2025, Current Assets fell 13.73% year-over-year to $485.1 million; the TTM value through Dec 2025 reached $485.1 million, down 13.73%, while the annual FY2025 figure was $485.1 million, 13.73% down from the prior year.
  • Current Assets was $485.1 million for Q4 2025 at Day One Biopharmaceuticals, down from $490.0 million in the prior quarter.
  • The five-year high for Current Assets was $581.0 million in Q3 2024, with the low at $326.0 million in Q1 2024.
  • Historically, Current Assets has averaged $451.4 million across 4 years, with a median of $467.4 million in 2023.
  • Biggest YoY gain for Current Assets was 56.01% in 2025; the steepest drop was 15.67% in 2025.
  • Over 4 years, Current Assets stood at $347.9 million in 2022, then rose by 7.88% to $375.3 million in 2023, then soared by 49.85% to $562.3 million in 2024, then dropped by 13.73% to $485.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $485.1 million in Q4 2025, $490.0 million in Q3 2025, and $494.4 million in Q2 2025.